Pubblicazioni

Autori:

Melisi, Davide; Casalino, Simona; Pietrobono, Silvia; Quinzii, Alberto; Zecchetto, Camilla; Merz, Valeria

Titolo:

Integration of liposomal irinotecan in the first-line treatment of metastatic pancreatic cancer: try to do not think about the white bear

Anno:

2024

Tipologia prodotto:

Articolo in Rivista

Tipologia ANVUR:

Articolo su rivista

Lingua:

Inglese

Referee:

No

Nome rivista:

THERAPEUTIC ADVANCES IN MEDICAL ONCOLOGY

ISSN Rivista:

1758-8340

N° Volume:

16

Intervallo pagine:

1-15

Parole chiave:

NALIRIFOX; liposomal irinotecan; pancreatic ductal adenocarcinoma

Breve descrizione dei contenuti:

The approval of novel therapeutic agents remains widely reliant on evidence derived from large phase III randomized controlled trials. Liposomal irinotecan (ONIVYDE (R)) stands out as the only drug that has demonstrated improved survival both as a first-line therapy in combination with oxaliplatin and 5-fluorouracil/leucovorin (5FU/LV) (NALIRIFOX) compared to the standard gemcitabine plus nab-paclitaxel in the NAPOLI3 trial, and as a second-line treatment in combination with 5FU/LV compared to the standard 5FU/LV in the NAPOLI1 trial. However, just as the white bear of the Dostoevsky's paradox, the judgment of these results is invariably distracted by the intrusive thought of how different they might be if compared to similar regimens containing standard-free irinotecan as FOLFIRINOX or FOLFIRI, respectively. Here, we present and thoroughly discuss the evidence encompassing the pharmacologic, preclinical, and clinical development of liposomal irinotecan that can dispel any intrusive thoughts and foster a rational and well-considered judgment of this agent and its potential integration into the therapeutic strategies for pancreatic ductal adenocarcinoma.

Id prodotto:

139426

Handle IRIS:

11562/1125830

ultima modifica:

31 ottobre 2024

Citazione bibliografica:

Melisi, Davide; Casalino, Simona; Pietrobono, Silvia; Quinzii, Alberto; Zecchetto, Camilla; Merz, Valeria, Integration of liposomal irinotecan in the first-line treatment of metastatic pancreatic cancer: try to do not think about the white bear «THERAPEUTIC ADVANCES IN MEDICAL ONCOLOGY» , vol. 16 , 2024 , pp. 1-15

Consulta la scheda completa presente nel repository istituzionale della Ricerca di Ateneo